Successful treatment of COVID‐19 with dexamethasone was originally highlighted by the Recovery Trial in the United Kingdom,17 and we observed elevated BMP9 concentrations mildly correlated with the duration of dexamethasone treatment (Figure 1q). The gene discussed is GDF2; the disease is COVID-19.